Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study

This multicenter, randomized, double-blind, parallel-controlled trial aimed to compare the pharmacokinetics (PK) of IBI301 with rituximab in patients with CD20-positive (CD20(+)) B-cell lymphoma, who achieved a complete response/unconfirmed complete response after standard treatments. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Bo, Ke, Xiaoyan, Zhang, Qingyuan, Xu, Wei, Su, Hang, Huang, Jie, Zhang, Mingzhi, Wang, Huaqing, Jin, Chuan, Zhu, Jun, Liu, Li, Cai, Zhen, Zhao, Xielan, Zhou, Jianfeng, Zhang, Xiaohong, Liu, Jing, Zhou, Hui, Yu, Jie, Sun, Xing, Qi, Junyuan, Qiu, Lugui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363910/
https://www.ncbi.nlm.nih.gov/pubmed/32669656
http://dx.doi.org/10.1038/s41598-020-68360-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363910/
https://www.ncbi.nlm.nih.gov/pubmed/32669656
http://dx.doi.org/10.1038/s41598-020-68360-0

Ejemplares similares